Novel Drug BI 1820237 Explored for Obesity, Alone and in Combination

Obesity and overweight are significant global health challenges, increasing the risk of numerous chronic diseases like type 2 diabetes and cardiovascular disease. Current treatments, while effective, often have room for improvement in terms of efficacy, tolerability, or novel mechanisms of action. This study addresses the knowledge gap regarding the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new investigational compound, BI 1820237, both as a standalone therapy and in combination with established or emerging anti-obesity medications.

The study, which started on April 11, 2023, and completed on August 1, 2024, primarily aimed to evaluate the safety and tolerability of BI 1820237. Key parameters investigated included the incidence and severity of adverse events, changes in vital signs, and laboratory parameters across various dosing regimens. The study also characterized the pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug) and pharmacodynamics (the drug's effects on the body) of BI 1820237 when given alone and in combination. The primary objective was to determine the safety and tolerability profile of BI 1820237 across different titration schedules, both as a monotherapy and when co-administered with semaglutide or BI 456906, providing crucial data for future development. While specific results on adverse event rates or pharmacokinetic profiles are not detailed in this protocol summary, the completion of the study indicates that these critical safety and drug-behavior data have been collected and are pending analysis.